Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study

PURPOSE: Tepotinib is a highly selective, potent, mesenchymal–epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping. Objectives of this population pharmacokinetic (PK) analysis were to evaluate the dose–exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wenyuan, Papasouliotis, Orestis, Jonsson, E. Niclas, Strotmann, Rainer, Girard, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054876/
https://www.ncbi.nlm.nih.gov/pubmed/35385993
http://dx.doi.org/10.1007/s00280-022-04423-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054876/
https://www.ncbi.nlm.nih.gov/pubmed/35385993
http://dx.doi.org/10.1007/s00280-022-04423-5

Ejemplares similares